Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo
Ya-Hui Chen,Yi-Chun Chen,Chi-Chen Lin,Yao-Peng Hsieh,Chien-Sheng Hsu,Ming-Chia Hsieh
DOI: https://doi.org/10.2147/CMAR.S247876
2020-06-17
Cancer Management and Research
Abstract:Ya-Hui Chen, 1, 2 Yi-Chun Chen, 1 Chi-Chen Lin, 3– 5 Yao-Peng Hsieh, 6– 8 Chien-Sheng Hsu, 9 Ming-Chia Hsieh 1, 10 1 Diabetes Research Laboratory, Department of Research, Changhua Christian Hospital, Changhua, Taiwan; 2 Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan; 3 Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan; 4 Department of Health and Nutrition, Asia University, Taichung, Taiwan; 5 Department of Medical Research, China Medical University Hospital, Taichung, Taiwan; 6 Division of General Internal Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 7 School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 8 School of Medicine, Chung Shan Medical University, Taichung, Taiwan; 9 Frontier Molecular Medical Research Center in Children, Changhua Christian Children Hospital, Changhua, Taiwan; 10 Intelligent Diabetes Metabolism and Exercise Center, China Medical University Hospital, Taichung, Taiwan Correspondence: Ming-Chia Hsieh Email D94750@mail.cmuh.org.tw Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient's chemotherapeutic initiation. Statins, including pitavastatin, have been indicated to have anticancer effects in numerous human cancer cell lines. Thus, in this study, we hypothesized that a combination of gemcitabine and pitavastatin may have a greater anticancer effect than gemcitabine alone on the human pancreatic carcinoma cell line MIA PaCa-2. Methods: The anticancer effects of gemcitabine with pitavastatin were evaluated using human MIA PaCa-2 cell line in vitro and in vivo Balb/c murine xenograft tumor model. Cell viability was assessed with CCK-8, and cell migration was stained by crystal violet. Cell cycle distribution, apoptosis and mitochondrial membrane potential were examined by flow cytometry. Activation of drug transporters (hENTs, hCNTs), intracellular drug activating (dCK) and inhibition of inactivating enzymes (RRMs) pathways were assessed by Western blotting analysis. Molecular mechanisms and signaling pathways of apoptosis, necrosis and autophagy also were assessed by Western blotting. Results: We observed that gemcitabine and pitavastatin synergistically suppressed the proliferation of MIA PaCa-2 cells through causing sub-G1 and S phase cell cycle arrest. Activation of apoptosis/necrosis was confirmed by annexin V/propidium iodide double staining, which showed increasing levels of active caspase 3, cleaved poly(ADP-ribose) polymerase and the RIP1–RIP3–MLKL complex. Moreover, gemcitabine–pitavastatin-mediated S phase arrest downregulated cyclin A2/CDK2 and upregulated p21/p27 in MIA PaCa-2 cells. Furthermore, this combination improved drug cellular metabolism pathway, mitochondria function and activated autophagy as part of the cell death mechanism. In vivo, gemcitabine-pitavastatin effectively inhibited tumor growth in a nude mouse mode of Mia PaCa-2 xenografts without observed adverse effect. Conclusion: Combined gemcitabine–pitavastatin may be an effective novel treatment option for pancreatic cancer. Keywords: synergistic anticancer, gemcitabine, pitavastatin, pancreatic cancer, MIA PaCa-2
oncology